Every 17α-alkylated oral stresses hepatocytes. This is not an ethical position. It is pharmacology: the methyl group at the C17 position that blocks 17β-hydroxyl glucuronidation — the liver’s primary clearance pathway for sex steroids — and grants oral bioavailability simultaneously forces hepatic detoxification onto a slower, glutathione-demanding alternative route. The liver works through the backed-up queue. Enzyme leakage into serum is the measured consequence.
Stanozolol, oxandrolone, oxymetholone, methandrostenolone, methyltestosterone, fluoxymesterone — every one is 17α-alkylated, every one is hepatotoxic to some degree. The literature on this is consistent across decades and across pharmacological reviews (Solimini et al. 2017, Eur Rev Med Pharmacol Sci; Hartgens & Kuipers 2004, Sports Med).
Injectable testosterone esters, nandrolone, boldenone, drostanolone, trenbolone, methenolone enanthate, and every researched peptide do not meaningfully elevate hepatocellular markers in otherwise-healthy subjects. Injectables bypass first-pass hepatic metabolism entirely; the alkylation chemistry that drives oral hepatotoxicity is absent. The liver was never the target organ for injectable esters.
The Four Enzymes That Matter
ALT (alanine aminotransferase) — reference 7–56 U/L for adult males (per Lala & Goyal, StatPearls 2023). The most hepatocyte-specific transaminase. On a 6-week oral protocol, expect ALT to rise 1.5–3× baseline. Values 80–120 U/L are common at standard methandrostenolone or oxandrolone doses and typically not clinically concerning in the short term. Above 3× upper reference limit (ULN) — over ~170 U/L — the threshold for clinical action activates per ACG 2014 drug-induced liver injury guidelines.
AST (aspartate aminotransferase) — reference 10–40 U/L. Less liver-specific than ALT — produced in skeletal muscle, cardiac muscle, and erythrocytes. Heavy training alone can push AST to 60–80 with normal liver function (Pettersson et al. 2008, BMC Musculoskelet Disord documented post-resistance-training AST elevation in healthy lifters reaching 5× ULN). Interpret AST only alongside ALT and CK; an AST:CK pattern with normal ALT discriminates muscle from hepatic origin.
GGT (gamma-glutamyl transferase) — reference 9–48 U/L. The most sensitive marker for cholestatic injury, rising before ALT on stanozolol, oxandrolone, and methandrostenolone exposures (Nasr & Ahmad 2009, Dig Dis Sci case report on Superdrol-induced cholestasis). Also sensitive to alcohol and to enzyme-inducing medications. If GGT triples while ALT is flat, the differential includes oral-AAS cholestatic injury, alcohol exposure, or recent acetaminophen use — order a full hepatic panel before attribution.
ALP (alkaline phosphatase) — reference 44–147 U/L. Elevated in cholestatic injury and in bone turnover. Paired GGT elevation confirms hepatic origin; isolated ALP elevation with normal GGT points to bone (Paget’s, fractures, intense osteoblast activity in younger users).
Bilirubin (total and direct) — reference total <1.2 mg/dL, direct <0.3 mg/dL. The functional readout. Direct bilirubin rising above 0.3 mg/dL signals clinical cholestasis irrespective of transaminase values; total bilirubin above 2 mg/dL with visible jaundice (sclerae yellowing) is a clinical emergency and warrants immediate cessation plus hepatology review.
The AST:ALT Ratio Differential
The AST:ALT ratio (also called the De Ritis ratio after the 1957 paper that first described it) discriminates hepatocellular damage patterns:
- AST:ALT ≈ 1:1 with ALT slightly higher — typical drug-induced liver injury, viral hepatitis, AAS hepatocellular pattern.
- AST:ALT >2 — alcoholic hepatitis pattern. Ethanol depletes hepatic pyridoxal-5-phosphate (the cofactor for ALT synthesis) more than for AST, producing the relatively higher AST.
- AST:ALT >1.5 with elevated CK — skeletal muscle origin. Common in heavy lifters drawn within 48 hours of training.
The pattern is documented across hepatology references including Botros & Sikaris, StatPearls AST:ALT ratio.
Cholestasis vs Hepatocellular Injury — The AAS-Specific Pattern
Oral 17α-alkylated AAS produce cholestatic liver injury more often than hepatocellular injury. The mechanism: the alkyl substituent disrupts canalicular bile-acid transport (specifically affecting BSEP and MDR3 transporters in hepatocyte canaliculi), producing intrahepatic cholestasis without primary hepatocyte necrosis. The pattern on bloodwork:
- ALP and GGT elevated disproportionately to ALT (cholestatic enzymes lead).
- Direct bilirubin rises before total bilirubin.
- ALT may be only mildly elevated even with significant cholestasis.
- Pruritus (itching) is the characteristic clinical symptom — bile salts deposit in skin.
Nasr & Ahmad 2009 documented severe cholestatic jaundice with renal involvement in a Superdrol user — the case became a reference for designer-steroid hepatotoxicity. Similar case series for oxymetholone include El Sherrif et al. 2013, BMJ Case Rep. Cholestatic injury is reversible within 4–8 weeks of stopping the compound in most cases; severe presentations (bilirubin >15 mg/dL) take longer and may require ursodeoxycholic acid therapy.
Hepatoprotective Protocol — Evidence Base
TUDCA (tauroursodeoxycholic acid) 500 mg/day: taurine conjugate of UDCA, the same molecule prescribed for primary biliary cholangitis. Mechanism: displaces hydrophobic membrane-toxic bile acids from the hepatic pool. Clinical evidence is solid in cholestatic disease (Vang et al. 2014, Glob Adv Health Med review of TUDCA mechanism); AAS-specific data is anecdotal but mechanistically aligned with the cholestatic injury pattern. Dose: 500 mg/day during oral use, ramp to 750–1000 mg/day for harsher compounds (oxymetholone, methyltestosterone).
N-acetylcysteine (NAC) 1200 mg/day: glutathione precursor; replenishes the cofactor depleted by alkylated-oral metabolism. Strongest direct evidence in acetaminophen overdose treatment (Smilkstein et al. 1988, NEJM — the foundational NAC study); AAS context is mechanism-extrapolated but biochemically coherent.
Milk thistle (silymarin) 420 mg/day: evidence is mixed. Meta-analyses split between modest benefit and statistically insignificant effect (Jacobs et al. 2002, Am J Med Cochrane-style review). The honest weakness is bioavailability — silymarin shows 20–50% oral absorption and extensive first-pass metabolism, limiting hepatic delivery. Cheap, low-risk, mechanistically reasonable; not first-tier.
Alcohol avoidance: not optional during orals. Ethanol via CYP2E1 is synergistic with the alkylated-oral hepatic load, not additive. Acetaminophen avoidance for the same reason — different pathway, similar synergistic risk.
Cycle duration ceiling: 6–8 weeks on most 17αA compounds. Oxandrolone is literature-tolerated for longer (the 2-oxa A-ring substitution reduces hepatic burden) but still carries cumulative risk past 8 weeks.
Action Thresholds
- ALT <2× ULN (<110): within expected range for 17αA exposure. Continue with hepatoprotection; recheck week 8.
- ALT 2–3× ULN (110–170): approaching upper end of expected. Reduce oral dose by 50%; recheck at 14 days.
- ALT >3× ULN (170+): end the oral. Continue testosterone base. Recheck in 3 weeks.
- ALT >5× ULN (250+): end immediately. Order full hepatic panel including GGT, ALP, bilirubin, INR, albumin. Recheck in 2 weeks.
- Direct bilirubin >0.3 mg/dL with cholestatic enzyme pattern: end immediately, clinical hepatology review.
- Total bilirubin >2 mg/dL with jaundice (sclerae yellowing): clinical emergency, immediate cessation, present to hepatology service.
AAS-induced elevation is reversible in almost every case if exit is timely. Injury that persists past 3 months off compound is uncommon but documented and warrants clinical workup for chronic liver disease (autoimmune hepatitis, viral hepatitis, NAFLD) that the AAS exposure may have unmasked rather than caused. “Push through” is not a defensible response to ALT >250 or rising bilirubin.
The Long-Term Cumulative Picture
Pope et al. 2013, Addiction reviewed adverse health effects of long-term AAS use including hepatic outcomes. The dominant finding: acute hepatic toxicity recovers consistently in young healthy users with timely cessation; chronic exposure across decades produces measurable hepatic remodelling that does not fully resolve. The clinical message: each individual oral cycle is recoverable; integrated lifetime exposure to 17α-alkylated compounds is the risk variable that does not reset.
For users on multi-cycle protocols, the defensible strategy limits oral compounds to short windows (6–8 weeks per cycle, 1–2 cycles per year) and substitutes longer cycle bulk with injectable compounds that bypass hepatic burden entirely. The pharmacology supports this approach more than it supports continuous or stacked oral use.